A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.

被引：0
|
作者：
Papadopoulos, K
Mendelson, D
Preston, GG
Lopez, AM
Ricart, AD
Schwartz, G
Needle, MN
Gordon, MS
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[3] Arizona Canc Ctr, Scottsdale, AZ USA
[4] Brooke Army Med Ctr, San Antonio, TX USA
[5] Celgene, Summit, NJ USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9116S / 9116S
页数：1
相关论文
共 50 条
  • [21] Phase I study of docetaxel (D), Carboplatin (C) and etoposide (E) in advanced solid tumors.
    Dunphy, F
    Dunleavy, T
    Cantrell, C
    Visconti, J
    Richart, J
    Pincus, S
    Petruska, P
    ANNALS OF ONCOLOGY, 2000, 11 : 135 - 135
  • [22] A phase I dose escalation study of docetaxel with G-CSF support given three weekly in patients with solid tumors.
    Mitchell, PLR
    Basser, R
    Ng, S
    Harris, M
    Chipman, M
    Grigg, A
    Mansfield, R
    Gargano, JA
    Jeffrey, AL
    Soulas, F
    Appia, F
    Green, M
    CLINICAL CANCER RESEARCH, 1999, 5 : 3731S - 3731S
  • [23] A dose escalation study of weekly docetaxel in patients with advanced solid tumors
    Ch. Kouroussis
    S. Agelaki
    D. Mavroudis
    J. Souglakos
    S. Kakolyris
    K. Kalbakis
    N. Vardakis
    D. Reppa
    D. Hatzidaki
    G. Samonis
    V. Georgoulias
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 488 - 492
  • [24] A dose escalation study of weekly docetaxel in patients with advanced solid tumors
    Kouroussis, C
    Agelaki, S
    Mavroudis, D
    Souglakos, J
    Kakolyris, S
    Kalbakis, K
    Vardakis, N
    Reppa, D
    Hatzidaki, D
    Samonis, G
    Georgoulias, V
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) : 488 - 492
  • [25] Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors
    Couteau, C
    Risse, ML
    Ducreux, M
    Lefresne-Soulas, F
    Riva, A
    Lebecq, A
    Ruffié, P
    Rougier, P
    Lokiec, F
    Bruno, R
    Armand, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) : 3545 - 3552
  • [26] Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors
    Nakanishi, Y
    Takayama, K
    Wataya, H
    Izumi, M
    Minami, T
    Takano, K
    Inoue, K
    Osaki, S
    Kimotsuki, K
    Harada, T
    Hara, N
    CHEMOTHERAPY, 2002, 48 (04) : 205 - 210
  • [27] Docetaxel and ifosfamide in patients with advanced solid tumors: Results of a phase I study
    Pronk, LC
    Schrijvers, D
    Schellens, JHM
    de Bruijn, EA
    Planting, AST
    Locci-Tonelli, D
    Groult, V
    Verweij, J
    van Oosterom, AT
    SEMINARS IN ONCOLOGY, 1998, 25 (01) : 23 - 28
  • [28] Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
    Pronk, LC
    Schellens, JHM
    Planting, AST
    vandenBent, MJ
    Hilkens, PHE
    vanderBurg, MEL
    deBoerDennert, M
    Ma, J
    Blanc, C
    Harteveld, M
    Bruno, R
    Stoter, G
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1071 - 1079
  • [29] A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors
    Witta, SE
    Gustafson, DL
    Pierson, AS
    Menter, A
    Holden, SN
    Basche, M
    Persky, M
    O'Bryant, CL
    Zeng, C
    Baron, A
    Long, ME
    Gibbs, A
    Kelly, K
    Bunn, PA
    Chan, DC
    Pallansch, P
    Eckhardt, SG
    CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7229 - 7237
  • [30] Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors.
    Moore, DJ
    Bahrani, A
    Hwang, JJ
    Ramzi, P
    Marshall, JL
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (02) : S391 - S391
12345